Research
Metabolic adaptation
The percentage of patients who had a glycated hemoglobin level of 6.5% or less was significantly higher in the cagrilintide-semaglutide group compared to the placebo group.
This treatment may significantly improve glycemic control in patients with type 2 diabetes.
StrongSupportsmedium confidence
The percentage of patients who had a glycated hemoglobin level of 6.5% or less was 73.5% in the cagrilintide-semaglutide group and 15.9% in the placebo group.
Why this rating
Supported by the trial's design and statistical significance.
Source
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Melanie J. Davies et al. · New England Journal of Medicine · 2025
rct · n=1206Cited 78×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →